Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Before Surgery in Head and Neck Squamous Cell Carcinoma
NCT03878979Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jul 2019
- Primary completion
- Oct 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Number of Participants With Drug-related Adverse Events and Number of Participants With Successful Completion of Preoperative Treatment. Started Jul 2019; status: completed.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03878979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03878979.